Spyre Therapeutics Prices $350 Million Common Stock Offering; Shares Down Pre-Bell
MT newswire2026/10/06 08:5904:59 AM EDT, 10/06/2026 (MT Newswires) -- Spyre Therapeutics (SYRE) priced an offering of about 4.12 million common shares at $85 each, targeting about $350 million in gross proceeds, the company said late Monday. Underwriters have a 30-day option to purchase up to an additional $52.5 million of shares. Spyre Therapeutics expects the offering to close by Wednesday and intends to use the net proceeds to continue to advance its programs in gastroenterology, rheumatology, and dermatology, among other things, it said. The company's shares were down 2.1% in premarket activity Tuesday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
